Modulating STAT3 Signaling by Selective C5aR1 Inhibition: An <i>In Silico</i> Directed <i>In Vitro</i> Approach to Combat Diabetic Kidney Disease

For Authors|For Editors|For Reviewers

Modulating STAT3 Signaling by Selective C5aR1 Inhibition: An In Silico Directed In Vitro Approach to Combat Diabetic Kidney Disease

Ayed A. Dera, Mesfer Al Shahrani

Discovery Medicine . 2025, (202): 2539 -2551 . DOI: 10.24976/Discov.Med.202537202.213

About Discovery Medicine
Editorial Board
Article Processing Charge
Submit

For Authors
For Editors
For Reviewers

Open Access Statement
Copyright & License
Digital Archive

Latest Issue
All Issues
Special Issues

By using this website, you agree to our Terms & Conditions and Privacy Policy.

Disclaimer

The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.